Get access

Use of lispro insulin for treatment of diabetic ketoacidosis in dogs

Authors

  • Kirk W. Sears DVM,

    Corresponding author
    • From the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA
    Search for more papers by this author
  • Kenneth J. Drobatz DVM, MSCE, DACVIM, DACVECC,

  • Rebecka S. Hess DVM, DACVIM


  • Presented as an abstract at the 27th Annual Veterinary Medical Forum, American College of Veterinary Internal Medicine, 2009, in Montreal, Canada.

  • This study was supported by a grant from the Department of Clinical Studies – Philadelphia, School of Veterinary Medicine, University of Pennsylvania.

  • The authors declare no conflict of interest.

Address correspondence and reprint requests to

Dr. Kirk W. Sears, Animal Diagnostic Clinic, 4444 Trinity Mills Rd, Suite 202, Dallas, TX 75287, USA.

Email: ksears@adcdallas.com

Abstract

Objectives

To characterize the use of lispro insulin in dogs with diabetes ketoacidosis (DKA) and to compare the length of time required for resolution of hyperglycemia, ketosis, and acidosis, respectively, in dogs with DKA treated with lispro or with regular insulin.

Design

Randomized prospective clinical trial performed between November 2006 and May 2009.

Setting

University teaching hospital.

Animals

Client-owned dogs with naturally occurring DKA. Dogs with a blood glucose (BG) > 13.9 mmol/L (>250 mg/dL), blood pH between 7.0 and 7.35, and a blood beta-hydroxybutyrate (BOHB) concentration >2.0 mmol/L were eligible to be enrolled into the study and were randomly assigned to receive an IV continuous rate infusion (CRI) of either lispro or regular insulin.

Interventions

Lispro or regular insulin was administered as an IV CRI at an initial dose of 0.09 U/kg/h. The dose was adjusted according to a previously published protocol.

Measurements and Main Results

Twelve dogs were enrolled into the study. The time to biochemical resolution of DKA was defined as the time interval from when the IV CRI of insulin began until marked hyperglycemia (BG > 13.9 mmol/L [>250 mg/dL]), acidosis (venous pH < 7.35), and ketosis (BOHB concentration >2.0 mmol/L) resolved. The median time to biochemical resolution of DKA in dogs treated with lispro insulin was significantly shorter (26 h; range 26–50 h) than in dogs treated with regular insulin (61 h; range, 38–80 h, P = 0.02). Median admission blood glucose concentration of all 12 dogs (24 mmol/L [432 mg/dL; range, 17.8–38.9 mmol/L [321–700 mg/dL]) decreased significantly with fluid resuscitation and prior to insulin therapy (20.5 mmol/L [369 mg/dL; range, 14.5–33.3 mmol/L [261–600 mg/dL], P = 0.0085). No adverse effects were observed in association with IV lispro insulin administration.

Conclusions

Treatment of DKA in dogs with IV CRI lispro insulin is safe, and as effective as treatment with regular insulin.

Get access to the full text of this article

Ancillary